局限性前列腺癌立体定向体部放疗的5年疗效结果
该研究分析2012-2015年接受机器人SBRT治疗的213例局限性前列腺癌患者的长期结果,中位随访64个月。低、中、高危组生化无复发生存率分别为100%、87.5%、80.0%(p=0.004),5年总生存率分别为97.9%、96.4%、88.6%,全队列疾病特异性生存率99.1%。结论认为SBRT在各风险组均获得优异长期疗效。
要点
- 低、中、高危组生化无复发生存率分别为100%、87.5%、80.0%(p=0.004)。
- 5年总生存率低、中、高危组分别为97.9%、96.4%、88.6%。
- 全队列疾病特异性生存率99.1%,仅2例高危患者死于前列腺癌。
核心结论
- SBRT治疗局限性前列腺癌获得优异的长期生化无复发生存、总生存和疾病特异性生存结局。
- SBRT为局限性前列腺癌患者提供有效且便捷的治疗选择,不受风险组限制。
研究设计与样本
- 非选择性真实世界患者队列,纳入2012-2015年接受机器人SBRT设备治疗的213例局限性前列腺癌患者。
主要发现
- 中位随访64个月(范围10-85个月),低、中、高危组分别有47例(22.1%)、56例(26.3%)、110例(51.6%)。
- 64.3%的患者接受了雄激素剥夺治疗(ADT)。
- 截至截点,低、中、高危组生化无复发生存率分别为100%、87.5%、80.0%(p=0.004)。
- Gleason评分≤6、7、≥8组生化无复发生存率分别为92.5%、84.2%、66.7%(p=0.001)。
- 5年总生存率低、中、高危组分别为97.9%、96.4%、88.6%;全队列疾病特异性生存率99.1%,仅2例高危患者死于前列腺癌。
临床怎么用
- SBRT可作为局限性前列腺癌各风险组的有效治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of stereotactic body radiotherapy (SBRT) as the primary treatment modality in clinically localized prostate cancer (PCa) is emerging. The aim of the study was to analyze the long-term results of PCa patients treated with SBRT. METHODS: This non-selected, real-life patient cohort included 213 patients with localized PCa treated with a robotic SBRT device during 2012-2015. RESULTS: The median follow-up was 64 months (range, 10-85 months), and all risk-groups were represented as 47 (22.1%), 56 (26.3%) and 110 (51.6%) patients were classified into D'Amico risk stratification of low, intermediate and high-risk groups, respectively. Androgen deprivation therapy (ADT) was administered to 64.3% of the patients. At cut-off, the biochemical relapse-free survival (bRFS) was 100, 87.5 and 80.0% for patients at low, intermediate and high-risk (p = 0.004), and 92.5, 84.2 and 66.7% for patients with Gleason score ≤ 6, 7 and ≥ 8, respectively (p = 0.001). The actuarial 5-year overall survival (OS) rates were 97.9, 96.4 and 88.6% in the low, intermediate and high-risk groups, respectively, and at the cut-off, the disease-specific survival (DSS) rate of the whole cohort was high (99.1%), as only two high-risk patients died due to PCa. CONCLUSION: Our present results of SBRT delivered with CyberKnife produced excellent long-term bRFS, OS and DSS outcomes among patients with localized PCa. We conclude that SBRT provides an efficient and convenient treatment option for patients with localized PCa, irrespective of the risk-group.
引用
- Vuolukka K, Auvinen P, Tiainen E, et al. Stereotactic body radiotherapy for localized prostate cancer - 5-year efficacy results. Radiat Oncol. 2020. PMID: 32664981. doi:10.1186/s13014-020-01608-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。